



PRESS RELEASE, OCTOBER 25, 2013

MOBERG PHARMA SIGNS DISTRIBUTION AGREEMENT IN MIDDLE EAST AND NORTH AFRICA

Moberg Pharma AB (OMX: MOB) today signed an exclusive agreement with Leosons International to distribute Moberg's Kerasal Nail™ in MENA (Middle East and North Africa). Leosons has been successfully distributing Moberg's JointFlex® brand in the Middle East for almost 10 years. Leosons intends to launch Kerasal Nail™ in 2014.

The agreement encompasses sixteen markets, including Egypt, Iraq, Saudi Arabia, Tunisia and UAE.

"We look forward to expanding our relationship with Leosons and making Kerasal Nail™ available across the MENA region. The region includes more than 200 million people and represents a growing market opportunity. We expect this agreement to contribute to revenues and earnings from 2014," said Peter Wolpert, President and CEO of Moberg Pharma AB.

About Kerasal Nail™ and nail disease

Kerasal Nail™ is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best-selling product in its category in the U.S. The international launch is under way via a proprietary sales organization in the U.S. and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia. Kerasal Nail™ is a prescription-free, over-the-counter product sold under the names Kerasal Nail™, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Kerasal Nail™ has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments.

For further information, please contact:

Peter Wolpert, CEO

Telephone: +46 8 522 307 00; Mobile: +46 707 35 71 35; E-mail: peter.wolpert@mobergpharma.se

Peter Östling, IR

Mobile: +46 76 314 09 78; Email: peter.ostling@mobergpharma.se

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 am (CET) on October 25, 2013.

About Moberg Pharma AB

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with its own sales organization in the US and sales through distributors in more than 40 countries. The company's product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail® and Kaprolac®. Kerasal Nail® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se.

About Leosons International AB

Leosons International distributes pharmaceuticals, OTC products and Medical Equipment over 6 continents, with a focus on the MENA region (Middle East and North Africa). For further information, please visit: www.leosonsinternational.com